Sickle Cell Disease, Neurocognitive Disorders, Social Participation

Sickle Cell Disease Clinical Trial

— SOCIODREP  

Official title:

Sickle Cell Disease, Neurocognitive Disorders, Social Participation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04793854
• Other study ID #: PAP_RNI_2018/02
• Status: Completed
• Start date: September 19, 2018
• Est. completion date: June 3, 2019

Study information

• Verified date: March 2021
• Source: Centre Hospitalier Universitaire de Pointe-a-Pitre
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This project will promote the development of transdisciplinary analyses. Neuropsychological disorders will be explored with the usual appropriate tests done by psychologists and neuropsychologists regularly involved in the management of sickle cell disease affected children. For the social sciences' component, various methods will be used: Measure of the Life habits (MHAVIE), Measure of Environmental Quality (MQE) and semi-guided interviews will complete the collection of qualitative data. The expected results concern the identification of the barriers or facilitators the sickle cell patients might face in their social participation, whether they are affected or not by neurological disorders.

Description:

Sickle cell anaemia, which is the most frequent genetic disease in France, requires an early and optimal care to reduce its morbidity and mortality. Children with sickle cell anaemia who are significantly anaemic may present neurological complications including stroke with or without clinical signs. A major risk associated to these strokes is the impairment of the general intellectual ability and learning ability, essentially resulting from neuropsychological disorders affecting intellectual functioning, executive and attentional functions. Although the negative impact of sickle cell anemia on the quality of life of the affected children and adolescents is well documented, no study has been focused on the role played by the neurocognitive disorders on their social participation. The objective of this project is the assessment of the influence of neurocognitive disorders in the social participation of children and adolescent with sickle cell anemia (6 to 16 years old), followed in Guadeloupe. This project will promote the development of transdisciplinary analyses. Neuropsychological disorders will be explored with the usual appropriate tests done by psychologists and neuropsychologists regularly involved in the management of sickle cell disease affected children. For the social sciences' component, various methods will be used: Measure of the Life habits (MHAVIE), Measure of Environmental Quality (MQE) and semi-guided interviews will complete the collection of qualitative data. The expected results concern the identification of the barriers or facilitators the sickle cell patients might face in their social participation, whether they are affected or not by neurological disorders

Recruitment information / eligibility

• Status: Completed
• Enrollment: 134
• Est. completion date: June 3, 2019
• Est. primary completion date: June 3, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years to 16 Years

Eligibility

Inclusion Criteria:

• Sickle cell anemia
• Age between 6 and 16 years inccuded, attending the centre of reference for sickle cell disease in Guadeloupe
• Informed consent
• Medical insurance

Exclusion Criteria:

• Other sickle cell syndrome other than SS or Sb-thal
• Less than 6 years old or older than 16
• Attending other sickle cell departments
• No medical insurance

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Neurocognitive Disorders
• Sickle Cell Disease

Intervention

Other:
• Measure of the Life habits (MHAVIE)
Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups). Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,…).

Locations

Country	Name	City	State
Guadeloupe	CHU de la Guadeloupe	Pointe-à-Pitre	France

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Pointe-a-Pitre	Université des Antilles, LAboratoire ACTES

Country where clinical trial is conducted

Guadeloupe, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MHAVIE-Children	Assessment of Life Habits-LIFE-H	Inclusion
Primary	MQE	Measure of Environmental Quality (MQE)	Inclusion